In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Carol Whelan
Carol Whelan
Carol Whelan Carol Whelan

University College London, London (United Kingdom of Great Britain & Northern Ireland)

Speciality : Acute Heart Failure

Dr Carol Whelan was appointed as Consultant Cardiologist with an interest in imaging, heart failure and cardiac amyloidosis, in October 2009 at the Royal Free London NHS Foundation Trust. She has been conferred the title of Honorary Associate Professor at UCL in recognition for her work at the National Amyloidosis Centre. She became the hospital clinical lead for Heart Failure in 2011. She was appointed lead for the Heart Failure Clinical Pathways Group work at the Trust in 2018. In November 2019, Dr Whelan was appointed as councillor on the board of the British Society for Heart Failure. She wrote the chapter on cardiac amyloidosis in the latest Oxford Textbook of Heart Failure and has published widely on this subject. As a clinical expert to NICE, she recently assisted them in their evaluation of two novel treatments, inotersen and patisiran, for hereditary transthyretin amyloidosis. These have both been approved.

1 presentation from this speaker

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are